ASCO GI 2021 | Real-world safety of second-line 5-FU regimens in mPDAC

Zev Wainberg, MD, University of California Los Angeles, Los Angeles, CA, outlines the real-world safety data and differentiation of second-line 5-FU based regimens in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).